Drugs / SHR-3167
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07489482 | Apr → Dec 2026 expected | diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07032688 | Aug 2025 → Mar 2027 expected | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07588906 | Feb → Jul 2024 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05996380 | Jun 2023 → Jan 2024 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07472725 | Apr → Dec 2026 expected | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07018453 | Jul 2025 → Feb 2026 overdue | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06688123 | Jan 2025 → Apr 2026 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-3167 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07032688 ↗ |
| Route | Subcutaneous | “subcutaneously injection of SHR-3167 or placebo” NCT05996380 ↗ |